Skip to main content

PRESS RELEASES

Date Title  
12/16/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 16, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors. Roger Pomerantz , M.D., has decided to step down after serving as Chairman of the Board since 2013. Dr.
11/14/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET . A live audio webcast of the presentation will be available under the
11/05/19
– Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate resources are expected to support operations into Q2 2021 – – Conference call at 8:30 a.m.
10/31/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 31, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general business update.
08/06/19
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs – - Completed public offering of common stock, raising net proceeds of $61M and extending the operating runway into 2021 – - Conference call at 8:00 a.m.
08/06/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced the appointment of Stephen Berenson to its Board of Directors. Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P.
08/01/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Canaccord Genuity 39 th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.m. ET . A live audio webcast of the presentation will be available
08/01/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on August 6, 2019 at 8:00 a.m. ET to discuss second quarter 2019 results and provide a general business update.
06/19/19
FDA alert does not impact Seres’ microbiome investigational therapeutic candidates CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) (“Seres”) today provided a statement on a safety alert from the U.S. Food and Drug Administration ( FDA ) regarding
06/13/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 13, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today

Back to top